Navigation Links
Progenitor Cell Therapy Appoints VP of Manufacturing Operations
Date:7/13/2009

PCT Recruits Experienced Pharmaceutical Production Executive to Head its Two U.S. Contract Manufacturing Facilities

Hackensack, NJ (Vocus) July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment of Daryl LeSueur as Vice President of Manufacturing Operations. As head of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of the manufacturing, packaging, and operational functions of PCT’s two North American contract manufacturing facilities.

Daryl brings to PCT over 25 years of experience in manufacturing operations in FDA-regulated industries. His experience includes proven leadership and success in developing and implementing operational initiatives to promote quality, reduce production costs, increase profitability and enhance operational efficiencies.

Prior to joining PCT, Daryl served as Vice President, Operations, Pomona, East Hanover and Northvale for Barr Laboratories. Before joining Barr, Daryl served as Vice President of Pharmaceutical Production at Novartis Pharmaceutical Corporation. At Novartis, he was responsible for managing all North American production operations, specializing in solid dosage, raw material and transdermal systems, and oversaw a $70 million budget. Prior to Novartis, Daryl was Associate Director of Pharmaceutical Production with Sandoz Pharmaceutical Company.

Daryl has a B.S. in Chemistry from the State University of New York at Plattsburgh and has completed the Leadership Program, Finance Program, and Management Program at Harvard Business School.

“We are very pleased to add someone with the caliber of Daryl’s experience to our senior management team,” states PCT Chief Executive Officer, Dr. Andrew L. Pecora. “Bringing on seasoned executives who can ensure the highest quality service to our customers and execute our growth strategy is a critical component of our strategic plan”.

“Daryl’s experience with highly regulated pharmaceutical-grade production environments is a critical skill set to our commercial-quality service offering and is the kind of cross-sector recruitment that will be important to continue as regenerative medicine matures into a commercial sector”, adds PCT President and Chief Scientific Officer, Dr. Robert A. Preti.

About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacturing, and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit www.progenitorcelltherapy.com.

Disclaimer
This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research, and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “intend,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2628514.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
5. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
6. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
7. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
8. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
9. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
10. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
11. Stem Cell Therapy to Skyrocket by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Progenitor Cell Therapy Appoints VP of Manufacturing Operations
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... announced that is has acquired Kendall Research Systems, LLC (KRS) clinical ... (MIT) that develops neural interface technology for research and clinical applications. The terms ...
(Date:2/22/2017)... Feb. 22, 2017 Scientists propose in ... organ damage in Gaucher and maybe other lysosomal storage ... lower costs than current therapies. An international ... Center , which also included investigators from the University ... their data Feb. 22. The study was conducted in ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is pleased to announce ... February 22 and 23, 2017. This premier, online-only conference focused on the development ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/3/2017)... WASHINGTON , Feb. 3, 2017 A ... Identity Strategy Partners, LLP (IdSP) . Designed to ... in the complex identity market, founding partners Mark ... nearly 35 combined years just in identity expertise that ... tank and non-profit leadership. The Crego-Kephart combined expertise has ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
Breaking Biology News(10 mins):